300294.SZ
300294.SZ
CNE100001FF1
BOYA BIOLOGY
Loading chart...

Company Profile

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection. In addition, it engages in research, development, production, and sales of anti-infective, diabetes, and cardiovascular drugs. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co.,Ltd. The company was founded in 1993 and is based in Fuzhou, China.

Related stocks

9887.HK
9887.HK • China
LEADS BIOLABS-B
45.56 HKD
1.15B USD 1Y -37.5%
300841.SZ
300841.SZ • China
KANGHUA BIOLOGICAL
55.26 CNY
1.07B USD 1Y -28.5%
688177.SS
688177.SS • China
BIO THERA SOLUTIONS LTD
19.3 CNY
1.2B USD 1Y -31.6%
688366.SS
688366.SS • China
SHANGHAI HAOHAI BIOLOGICAL TECH
30.77 CNY
1.03B USD 1Y -41%
1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%
688739.SS
688739.SS • China
LIAONING CHENGDA BIOTECHNOLOGY
21.2 CNY
1.32B USD 1Y -21.9%
002030.SZ
002030.SZ • China
DAJY
6.03 CNY
1.27B USD 1Y -6.1%
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
32.8% p.a.
Max Drawdown (5Y)
-67.3%
Sharpe Ratio (5Y)
-0.56
Beta Factor
0.40
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (32.8% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -75.4% in the extended horizon.
ende